Jacc: Cardiooncology最新文献

{"title":"The United Kingdom’s First Cardio-Oncology Service","authors":"Maria Sol Andres MD , Theodore Murphy MBBS, MSc , Nana Poku MD , Muhummad Sohaib Nazir MBBS, PhD , Sivatharshini Ramalingam MBBS , John Baksi MBBS, PhD , Julian W.E. Jarman MD(Res) , Rajdeep Khattar DM , Rakesh Sharma MBBS, PhD , Stuart D. Rosen MA, MD , Alexander R. Lyon MBBS, PhD","doi":"10.1016/j.jaccao.2023.12.003","DOIUrl":"10.1016/j.jaccao.2023.12.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000012/pdfft?md5=2060076c7890220f2afa6d919209fe87&pid=1-s2.0-S2666087324000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139888360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"(Less) Time and Energy","authors":"Logan G. Kirkland BS , Brian C. Jensen MD","doi":"10.1016/j.jaccao.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.jaccao.2024.03.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000619/pdfft?md5=00741faf1119609e62522bf89a4f275b&pid=1-s2.0-S2666087324000619-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?","authors":"Haoyi Zheng MD, PhD , Huichun Zhan MD","doi":"10.1016/j.jaccao.2024.01.004","DOIUrl":"10.1016/j.jaccao.2024.01.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000115/pdfft?md5=ae3a933f31763bb148bc1f07e3aae194&pid=1-s2.0-S2666087324000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139889019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity","authors":"Hanne M. Boen MD ,&nbsp;Martina Cherubin MSc ,&nbsp;Constantijn Franssen MD, PhD ,&nbsp;Andreas B. Gevaert MD, PhD ,&nbsp;Isabel Witvrouwen MD, PhD ,&nbsp;Matthias Bosman PhD ,&nbsp;Pieter-Jan Guns PhD ,&nbsp;Hein Heidbuchel MD, PhD ,&nbsp;Bart Loeys MD, PhD ,&nbsp;Maaike Alaerts PhD ,&nbsp;Emeline M. Van Craenenbroeck MD, PhD","doi":"10.1016/j.jaccao.2023.12.009","DOIUrl":"10.1016/j.jaccao.2023.12.009","url":null,"abstract":"<div><p>Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial for early diagnosis and therapy guidance. Currently, monitoring relies on cardiac imaging and serial measurement of cardiac biomarkers like cardiac troponin and natriuretic peptides. However, these conventional biomarkers are nonspecific indicators of cardiac damage. Exploring new, more specific biomarkers with a clear link to the underlying pathomechanism of cardiotoxicity holds promise for increased specificity and sensitivity in detecting early anthracycline-induced cardiotoxicity. miRNAs (microRNAs), small single-stranded, noncoding RNA sequences involved in epigenetic regulation, influence various physiological and pathological processes by targeting expression and translation. Emerging as new biomarker candidates, circulating miRNAs exhibit resistance to degradation and offer a direct pathomechanistic link. This review comprehensively outlines their potential as early biomarkers for cardiotoxicity and their pathomechanistic link.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000127/pdfft?md5=265bcc23dd36424e8f07ecb4b818deec&pid=1-s2.0-S2666087324000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140468362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors","authors":"Jan M. Leerink MD ,&nbsp;Elizabeth A.M. Feijen MD, PhD ,&nbsp;Esmee C. de Baat MD ,&nbsp;Remy Merkx MD ,&nbsp;Helena J.H. van der Pal MD, PhD ,&nbsp;Wim J.E. Tissing MD, PhD ,&nbsp;Marloes Louwerens MD ,&nbsp;Marry M. van den Heuvel-Eibrink MD, PhD ,&nbsp;A. Birgitta Versluys MD, PhD ,&nbsp;Elvira C. van Dalen MD, PhD ,&nbsp;Margriet van der Heiden-van der Loo PhD ,&nbsp;Dorine Bresters MD, PhD ,&nbsp;Cécile M. Ronckers PhD ,&nbsp;Andrica C.H. de Vries MD, PhD ,&nbsp;Sebastian Neggers MD, PhD ,&nbsp;Livia Kapusta MD, PhD ,&nbsp;Jacqueline Loonen MD, PhD ,&nbsp;Yigal M. Pinto MD, PhD ,&nbsp;Leontien C.M. Kremer MD, PhD ,&nbsp;Annelies M.C. Mavinkurve-Groothuis MD, PhD ,&nbsp;Wouter E.M. Kok MD, PhD","doi":"10.1016/j.jaccao.2024.02.008","DOIUrl":"https://doi.org/10.1016/j.jaccao.2024.02.008","url":null,"abstract":"<div><h3>Background</h3><p>Childhood cancer survivors at risk for heart failure undergo lifelong echocardiographic surveillance. Previous studies reported the limited diagnostic accuracy of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) in detecting left ventricular (LV) dysfunction. However, potential enhanced diagnostic accuracy through the combination of biomarkers and clinical characteristics has been suggested.</p></div><div><h3>Objectives</h3><p>The aim of this study was to develop and internally validate a diagnostic model that combines cardiac biomarkers with clinical characteristics for effectively ruling in or ruling out LV dysfunction in childhood cancer survivors.</p></div><div><h3>Methods</h3><p>A multicenter cross-sectional study included 1,334 survivors (median age 34.2 years) and 278 siblings (median age 36.8 years). Logistic regression models were developed and validated through bootstrapping, combining biomarkers with clinical characteristics.</p></div><div><h3>Results</h3><p>Abnormal NT-proBNP levels were observed in 22.1% of survivors compared with 5.4% of siblings, whereas hs-cTnT levels exceeding 10 ng/L were uncommon in both survivors (5.9%) and siblings (5.0%). The diagnostic models demonstrated improvement upon the addition of NT-proBNP and hs-cTnT to clinical characteristics, resulting in an increased C statistic from 0.69 to 0.73 for LV ejection fraction (LVEF) &lt;50% and a more accurate prediction of more severe LV dysfunction, with the C statistic increasing from 0.80 to 0.86 for LVEF &lt;45%. For LVEF &lt;50% (prevalence 10.9%), 16.9% of survivors could be effectively ruled out with high sensitivity (95.4%; 95% CI: 90.4%-99.3%) and negative predictive value (97.5%; 95% CI: 94.6%-99.7%). Similarly, for LVEF &lt;45% (prevalence 3.4%), 53.0% of survivors could be ruled out with moderate to high sensitivity (91.1%; 95% CI: 79.2%-100%) and high negative predictive value (99.4%; 95% CI: 98.7%-100%).</p></div><div><h3>Conclusions</h3><p>The biomarker-based diagnostic model proves effective in ruling out LV dysfunction, offering the potential to minimize unnecessary surveillance echocardiography in childhood cancer survivors. External validation is essential to confirm these findings. (Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors; A DCOG LATER Study; <span>https://onderzoekmetmensen.nl/nl/trial/23641</span><svg><path></path></svg>)</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000620/pdfft?md5=1daa75969db868061aeae2b08e898bbd&pid=1-s2.0-S2666087324000620-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Learning From Trials","authors":"Laura Obici MD ,&nbsp;Roberta Mussinelli MD, PhD ,&nbsp;Giovanni Palladini MD, PhD","doi":"10.1016/j.jaccao.2024.03.004","DOIUrl":"https://doi.org/10.1016/j.jaccao.2024.03.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000656/pdfft?md5=b191faeb3880e8ecad48aba9b2f7e6b7&pid=1-s2.0-S2666087324000656-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials","authors":"Stephen Rankin MBChB ,&nbsp;Benjamin Elyan MBChB ,&nbsp;Robert Jones MBChB, PhD ,&nbsp;Balaji Venugopal MBBS, MD ,&nbsp;Patrick B. Mark MBChB, PhD ,&nbsp;Jennifer S. Lees MA, PhD ,&nbsp;Mark C. Petrie MBChB ,&nbsp;Ninian N. Lang MBChB, PhD","doi":"10.1016/j.jaccao.2023.12.010","DOIUrl":"10.1016/j.jaccao.2023.12.010","url":null,"abstract":"<div><h3>Background</h3><p>Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitors (VEGFIs) has improved cancer outcomes and is increasingly used. These drug classes are associated with cardiovascular toxicities when used alone, but heterogeneity in trial design and reporting may limit knowledge of toxicities in patients receiving these in combination.</p></div><div><h3>Objectives</h3><p>The aim of this study was to assess consistency and clarity in definitions and reporting of cardiovascular eligibility criteria, baseline characteristics, and cardiovascular adverse events in ICI and VEGFI combination trials.</p></div><div><h3>Methods</h3><p>A scoping review was conducted of phase 2 to 4 randomized controlled trials of ICI and VEGFI combination therapy for solid tumors. Trial cardiovascular eligibility criteria and baseline cardiovascular characteristic reporting in trial publications was assessed, and cardiovascular adverse event definitions and reporting criteria were also examined.</p></div><div><h3>Results</h3><p>Seventeen trials (N = 10,313; published 2018-2022) were included. There were multiple cardiovascular exclusion criteria in 15 trials. No primary trial publication reported baseline cardiovascular characteristics. Thirteen trials excluded patients with prior heart failure, myocardial infarction, hypertension, or stroke. There was heterogeneity in defining cardiovascular conditions. “Grade 1 to 4” cardiovascular adverse events were reported when incidence was ≥5% to 25% in 15 trials. Incident hypertension was recorded in all trials, but other cardiovascular events were not consistently reported. No trial specifically noted the absence of cardiovascular events.</p></div><div><h3>Conclusions</h3><p>In ICI and VEGFI combination trials, there is heterogeneity in cardiovascular exclusion criteria, reporting of baseline characteristics, and reporting of cardiovascular adverse events. This limits an optimal understanding of the incidence and severity of events relating to these combinations. Better standardization of these elements should be pursued. (Exclusions and Representation of Patients With Kidney Disease and Cardiovascular Disease in Drug Trials of the Novel Systemic Anti-Cancer Therapies VEGF-Signalling Pathway Inhibitors Alone or in Combination With Immune Checkpoint Inhibitors; <span>CRD42022337942</span><svg><path></path></svg>)</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000462/pdfft?md5=7fa88fa5522cd5107148ba9ad69f45e2&pid=1-s2.0-S2666087324000462-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140465601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board/Officers Page","authors":"","doi":"10.1016/S2666-0873(24)00067-X","DOIUrl":"https://doi.org/10.1016/S2666-0873(24)00067-X","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266608732400067X/pdfft?md5=4004b063372891a748c23a6754798e6d&pid=1-s2.0-S266608732400067X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control","authors":"Anabel Díaz-Guerra MSc ,&nbsp;Rocío Villena-Gutiérrez PhD ,&nbsp;Agustín Clemente-Moragón PhD ,&nbsp;Mónica Gómez Tech ,&nbsp;Eduardo Oliver PhD ,&nbsp;Miguel Fernández-Tocino MSc ,&nbsp;Carlos Galán-Arriola DVM, PhD ,&nbsp;Laura Cádiz PhD ,&nbsp;Borja Ibáñez MD, PhD","doi":"10.1016/j.jaccao.2024.02.005","DOIUrl":"https://doi.org/10.1016/j.jaccao.2024.02.005","url":null,"abstract":"<div><h3>Background</h3><p>Anthracycline-induced cardiotoxicity (AIC) debilitates quality of life in cancer survivors. Serial characterizations are lacking of the molecular processes occurring with AIC.</p></div><div><h3>Objectives</h3><p>The aim of this study was to characterize AIC progression in a mouse model from early (subclinical) to advanced heart failure stages, with an emphasis on cardiac metabolism and mitochondrial structure and function.</p></div><div><h3>Methods</h3><p>CD1 mice received 5 weekly intraperitoneal doxorubicin injections (5 mg/kg) and were followed by serial echocardiography for 15 weeks. At 1, 9, and 15 weeks after the doxorubicin injections, mice underwent fluorodeoxyglucose positron emission tomography, and hearts were extracted for microscopy and molecular analysis.</p></div><div><h3>Results</h3><p>Cardiac atrophy was evident at 1 week post-doxorubicin (left ventricular [LV] mass 117 ± 26 mg vs 97 ± 25 mg at baseline and 1 week, respectively; <em>P</em> &lt; 0.001). Cardiac mass nadir was observed at week 3 post-doxorubicin (79 ± 16 mg; <em>P</em> = 0.002 vs baseline), remaining unchanged thereafter. Histology confirmed significantly reduced cardiomyocyte area (167 ± 19 μm² in doxorubicin-treated mice vs 211 ± 26 μm² in controls; <em>P</em> = 0.004). LV ejection fraction declined from week 6 post-doxorubicin (49% ± 9% vs 61% ± 9% at baseline; <em>P</em> &lt; 0.001) until the end of follow-up at 15 weeks (43% ± 8%; <em>P</em> &lt; 0.001 vs baseline). At 1 week post-doxorubicin, when LV ejection fraction remained normal, reduced cardiac metabolism was evident from down-regulated markers of fatty acid oxidation and glycolysis. Metabolic impairment continued to the end of follow-up in parallel with reduced mitochondrial adenosine triphosphate production. A transient early up-regulation of nutrient-sensing and mitophagy markers were observed, which was associated with mitochondrial enlargement. Later stages, when mitophagy was exhausted, were characterized by overt mitochondrial fragmentation.</p></div><div><h3>Conclusions</h3><p>Cardiac atrophy, global hypometabolism, early transient-enhanced mitophagy, biogenesis, and nutrient sensing constitute candidate targets for AIC prevention.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000589/pdfft?md5=a0f64800e8b31200b29d652f45cbed0c&pid=1-s2.0-S2666087324000589-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan∗","authors":"Wei Xiong MD, PhD ,&nbsp;Yugo Yamashita MD, PhD","doi":"10.1016/j.jaccao.2024.02.002","DOIUrl":"https://doi.org/10.1016/j.jaccao.2024.02.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":11.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000553/pdfft?md5=4d43f2b5b158dbf64f7618701ac0d122&pid=1-s2.0-S2666087324000553-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140559243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}